$ARDX
ARDELYX, INC.

2016 Q3 Form 10-Q Financial Statement

#000119312516675135 Filed on August 08, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $0.00 $0.00 $18.14M
YoY Change -100.0% 98.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.340M $4.850M $2.890M
YoY Change 28.78% 67.82% 140.83%
% of Gross Profit
Research & Development $24.86M $23.84M $6.198M
YoY Change 69.08% 284.61% 19.58%
% of Gross Profit
Depreciation & Amortization $270.0K $320.0K $160.0K
YoY Change 3.85% 100.0% 166.67%
% of Gross Profit
Operating Expenses $29.20M $28.69M $9.087M
YoY Change 61.51% 215.73% 42.3%
Operating Profit -$29.20M -$28.69M $9.056M
YoY Change 61.51% -416.81% 229.19%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit 0.0%
Other Income/Expense, Net $169.0K $77.00K -$49.00K
YoY Change -319.48% -257.14% 512.5%
Pretax Income -$29.03M -$28.61M $9.007M
YoY Change 59.9% -417.68% 139.99%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$29.03M -$28.61M $9.007M
YoY Change 60.16% -417.68% 139.99%
Net Earnings / Revenue 49.64%
Basic Earnings Per Share -$0.83 $0.43
Diluted Earnings Per Share -$646.0K -$0.83 $0.42
COMMON SHARES
Basic Shares Outstanding 47.25M shares 34.64M shares 20.88M shares
Diluted Shares Outstanding 34.64M shares 21.64M shares

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $230.1M $146.7M $141.5M
YoY Change 78.36% 3.67% 20.12%
Cash & Equivalents $160.4M $146.7M $141.5M
Short-Term Investments $69.73M
Other Short-Term Assets $4.100M $3.700M $2.400M
YoY Change -6.82% 54.17% 84.62%
Inventory
Prepaid Expenses
Receivables $27.00K
Other Receivables $0.00
Total Short-Term Assets $234.2M $150.4M $143.9M
YoY Change 75.47% 4.5% 17.87%
LONG-TERM ASSETS
Property, Plant & Equipment $6.969M $4.827M $4.061M
YoY Change 58.71% 18.86% 269.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $148.0K $148.0K $104.0K
YoY Change 42.31% 42.31% -48.0%
Total Long-Term Assets $7.117M $4.975M $4.265M
YoY Change 54.89% 16.65% 204.64%
TOTAL ASSETS
Total Short-Term Assets $234.2M $150.4M $143.9M
Total Long-Term Assets $7.117M $4.975M $4.265M
Total Assets $241.3M $155.4M $148.2M
YoY Change 74.78% 4.85% 19.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.298M $4.746M $2.684M
YoY Change 132.06% 76.83% 16.7%
Accrued Expenses $10.50M $8.500M $2.900M
YoY Change 517.65% 193.1% 61.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.64M $14.06M $5.546M
YoY Change 40.14% 153.53% -79.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $789.0K $713.0K $382.0K
YoY Change 124.15% 86.65% -98.85%
Total Long-Term Liabilities $789.0K $713.0K $382.0K
YoY Change 124.15% 86.65% -98.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.64M $14.06M $5.546M
Total Long-Term Liabilities $789.0K $713.0K $382.0K
Total Liabilities $18.42M $14.77M $5.928M
YoY Change 42.42% 149.22% -90.22%
SHAREHOLDERS EQUITY
Retained Earnings -$182.6M -$153.6M -$66.36M
YoY Change 116.13% 131.41%
Common Stock $405.5M $294.2M $208.6M
YoY Change 93.46% 41.01% 10431000.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $222.9M $140.6M $142.3M
YoY Change
Total Liabilities & Shareholders Equity $241.3M $155.4M $148.2M
YoY Change 74.78% 4.85% 19.99%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$29.03M -$28.61M $9.007M
YoY Change 60.16% -417.68% 139.99%
Depreciation, Depletion And Amortization $270.0K $320.0K $160.0K
YoY Change 3.85% 100.0% 166.67%
Cash From Operating Activities -$24.82M -$24.90M -$30.22M
YoY Change 110.16% -17.6% -225.97%
INVESTING ACTIVITIES
Capital Expenditures -$1.610M -$300.0K -$1.260M
YoY Change 136.76% -76.19% 93.85%
Acquisitions
YoY Change
Other Investing Activities -$69.74M
YoY Change
Cash From Investing Activities -$71.35M -$300.0K -$1.260M
YoY Change 10392.65% -76.19% 93.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $74.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 109.9M 190.0K 74.70M
YoY Change -99.75% 21.98%
NET CHANGE
Cash From Operating Activities -24.82M -24.90M -30.22M
Cash From Investing Activities -71.35M -300.0K -1.260M
Cash From Financing Activities 109.9M 190.0K 74.70M
Net Change In Cash 13.70M -25.01M 43.22M
YoY Change -209.69% -157.87% -48.9%
FREE CASH FLOW
Cash From Operating Activities -$24.82M -$24.90M -$30.22M
Capital Expenditures -$1.610M -$300.0K -$1.260M
Free Cash Flow -$23.21M -$24.60M -$28.96M
YoY Change 108.54% -15.06% -217.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47250496 shares
CY2015Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.125
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141534000
CY2015Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2172899 shares
CY2015Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.70
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2038000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34650266 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34650266 shares
CY2016Q2 us-gaap Assets
Assets
155379000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
150404000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
294171000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
146669000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4746000
CY2016Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7277000
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
771000
CY2016Q2 us-gaap Liabilities
Liabilities
14774000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
155379000
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
713000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14061000
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
148000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4827000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
140605000
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153570000
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3735000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2366000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
210386000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107004000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2777000
CY2015Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2580000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1328000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
380000
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 ardx Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
4202000
CY2016Q2 ardx Accrued Contract Manufacturing Costs
AccruedContractManufacturingCosts
1694000
CY2016Q2 ardx Accrued Professional And Consultant Fees Current
AccruedProfessionalAndConsultantFeesCurrent
610000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107286000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25964886 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25964886 shares
CY2015Q4 us-gaap Assets
Assets
116946000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
112031000
CY2015Q4 us-gaap Liabilities
Liabilities
8045000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116946000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
322000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7723000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4711000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
108901000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101488000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
100000
CY2015Q4 ardx Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
311000
CY2015Q4 ardx Accrued Contract Manufacturing Costs
AccruedContractManufacturingCosts
289000
CY2015Q4 ardx Accrued Professional And Consultant Fees Current
AccruedProfessionalAndConsultantFeesCurrent
272000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
400000 shares
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
34248000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1165000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
134000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6064000
us-gaap Revenues
Revenues
24026000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
886000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-192000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-61000
us-gaap Licenses Revenue
LicensesRevenue
21611000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-11000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
310000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-47053000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
us-gaap Depreciation
Depreciation
278000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
us-gaap Operating Expenses
OperatingExpenses
18460000
us-gaap Net Income Loss
NetIncomeLoss
5505000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5505000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2320000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2557000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-631000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
959000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
724890 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
5566000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
75001000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-38433000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2320000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
74654000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20506916 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19749778 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12396000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
317000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
30000
us-gaap Share Based Compensation
ShareBasedCompensation
1165000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2415000
ardx Weighted Average Private Placement Warrants Outstanding
WeightedAveragePrivatePlacementWarrantsOutstanding
32248 shares
ardx Common Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
CommonStockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
287000
ardx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
5505000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
174000
dei Entity Registrant Name
EntityRegistrantName
Ardelyx, Inc.
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4600000 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001437402
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
39665000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2476000
us-gaap Cost Of Services Amortization
CostOfServicesAmortization
101000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
252000
us-gaap Net Income Loss
NetIncomeLoss
-52082000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
5089000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
139000
us-gaap Operating Expenses
OperatingExpenses
52221000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9130000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
us-gaap Depreciation
Depreciation
631000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52082000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-495000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1717000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1073000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52221000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
81309000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-328000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-41149000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
495000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
80837000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although management believes these estimates are based upon reasonable assumptions within the bounds of its knowledge of the Company&#x2019;s business and operations, actual results could differ materially from those estimates.</p> </div>
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34051785 shares
CY2016Q1 ardx Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
86300000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000 shares
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
641000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2889000
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.43
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
CY2015Q2 us-gaap Revenues
Revenues
18143000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34051785 shares
dei Trading Symbol
TradingSymbol
ARDX
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43091000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
472000
us-gaap Share Based Compensation
ShareBasedCompensation
2476000
ardx Class Of Warrant Or Right Expiration Date Description
ClassOfWarrantOrRightExpirationDateDescription
The warrants are exercisable at an exercise price of $13.91 per share at any time prior to the earlier of (i) 5 years from the date of issuance or (ii) certain changes in control of the Company.
ardx Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
0 shares
ardx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-52082000
CY2015Q2 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
13.91
CY2015Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
74300000
CY2015Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7242992 shares
CY2015Q2 ardx Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
77800000
CY2015Q2 ardx Class Of Warrant Or Right Threshold Ownership Percentage
ClassOfWarrantOrRightThresholdOwnershipPercentage
0.0999 pure
CY2015Q2 ardx Warrant Expiration Term
WarrantExpirationTerm
P5Y
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
80800000
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8625000 shares
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-49000
CY2015Q2 us-gaap Licenses Revenue
LicensesRevenue
17727000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
9087000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
9007000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9007000
CY2015Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
692110 shares
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
9056000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21636487 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20880235 shares
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6198000
CY2015Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
416000
CY2015Q2 ardx Weighted Average Private Placement Warrants Outstanding
WeightedAveragePrivatePlacementWarrantsOutstanding
64142 shares
CY2015Q2 ardx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
9007000
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4700000 shares
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1286000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4852000
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
77000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
28690000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-28613000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28613000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-28690000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34636559 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34636559 shares
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23838000
CY2016Q2 ardx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-28613000

Files In Submission

Name View Source Status
0001193125-16-675135-index-headers.html Edgar Link pending
0001193125-16-675135-index.html Edgar Link pending
0001193125-16-675135.txt Edgar Link pending
0001193125-16-675135-xbrl.zip Edgar Link pending
ardx-20160630.xml Edgar Link completed
ardx-20160630.xsd Edgar Link pending
ardx-20160630_cal.xml Edgar Link unprocessable
ardx-20160630_def.xml Edgar Link unprocessable
ardx-20160630_lab.xml Edgar Link unprocessable
ardx-20160630_pre.xml Edgar Link unprocessable
d201246d10q.htm Edgar Link pending
d201246dex101.htm Edgar Link pending
d201246dex102.htm Edgar Link pending
d201246dex103.htm Edgar Link pending
d201246dex311.htm Edgar Link pending
d201246dex312.htm Edgar Link pending
d201246dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201246g0805090146319.jpg Edgar Link pending
g201246g0805090147053.jpg Edgar Link pending
g201246g0805090147225.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending